These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 17597479

  • 1. Long-term administration of the low-dose risperidone in schizotaxia subjects.
    Rybakowski JK, Drozdz W, Borkowska A.
    Hum Psychopharmacol; 2007 Aug; 22(6):407-12. PubMed ID: 17597479
    [Abstract] [Full Text] [Related]

  • 2. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW, Shin IS, Kim JM, Lee SH, Lee YH, Yang SJ, Yoon JS.
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [Abstract] [Full Text] [Related]

  • 3. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
    Lee SM, Chou YH, Li MH, Wan FJ, Yen MH.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun 30; 31(5):1101-7. PubMed ID: 17475386
    [Abstract] [Full Text] [Related]

  • 4. Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically?: Results from the Changsha study.
    Stone WS, Hsi X, Giuliano AJ, Tan L, Zhu S, Li L, Seidman LJ, Tsuang MT.
    Asian J Psychiatr; 2012 Mar 30; 5(1):73-82. PubMed ID: 22489255
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Factors connected with the effect of risperidone on psychopathological symptoms and working memory in schizophrenia].
    Borkowska A, Rybakowski J.
    Psychiatr Pol; 2002 Mar 30; 36(6 Suppl):225-33. PubMed ID: 12647443
    [Abstract] [Full Text] [Related]

  • 7. [Long-term effects of the treatment with risperidone versus conventional neuroleptics on the neuropsychological performance of euthymic bipolar patients].
    Reinares M, Martínez-Arán A, Colom F, Benabarre A, Salamero M, Vieta E.
    Actas Esp Psiquiatr; 2000 Mar 30; 28(4):231-8. PubMed ID: 11116794
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec 30; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 10. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
    Gharabawi G, Bossie C, Turkoz I, Kujawa M, Mahmoud R, Simpson G.
    J Nerv Ment Dis; 2007 Dec 30; 195(12):976-82. PubMed ID: 18091190
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
    Chen ZH, Wang GH, Wang XP, Chen RY, Wang HL, Yang MH, Huo YX, Mei HB.
    Hum Psychopharmacol; 2008 Aug 30; 23(6):465-70. PubMed ID: 18536066
    [Abstract] [Full Text] [Related]

  • 13. Long-acting risperidone improves negative symptoms in stable psychotic patients.
    Curtis VA, Katsafouros K, Möller HJ, Medori R, Sacchetti E.
    J Psychopharmacol; 2008 May 30; 22(3):254-61. PubMed ID: 18308804
    [Abstract] [Full Text] [Related]

  • 14. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C, Dusouchet T, Bret P, Queuille E, Biscay ML, Caron J, Bret MC.
    Encephale; 2007 Dec 30; 33(6):973-81. PubMed ID: 18789790
    [Abstract] [Full Text] [Related]

  • 15. Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers.
    Barrett SL, Bell R, Watson D, King DJ.
    J Psychopharmacol; 2004 Jun 30; 18(2):156-72. PubMed ID: 15260903
    [Abstract] [Full Text] [Related]

  • 16. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.
    Encephale; 2008 Dec 30; 34(6):557-62. PubMed ID: 19081451
    [Abstract] [Full Text] [Related]

  • 17. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
    Rocca P, Montemagni C, Castagna F, Giugiario M, Scalese M, Bogetto F.
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar 17; 33(2):373-9. PubMed ID: 19211031
    [Abstract] [Full Text] [Related]

  • 18. Risperidone in the treatment of schizotypal personality disorder.
    Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman RL, Silverman J, Siever LJ.
    J Clin Psychiatry; 2003 Jun 17; 64(6):628-34. PubMed ID: 12823075
    [Abstract] [Full Text] [Related]

  • 19. Validating schizotaxia and its place in studies of preventing schizophrenia by psychopharmacological intervention.
    Tsuang MT, Stone WS, Tarbox SI, Faraone SV.
    Essent Psychopharmacol; 2005 Jun 17; 6(2):91-103. PubMed ID: 15765793
    [Abstract] [Full Text] [Related]

  • 20. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.
    Kawai N, Yamakawa Y, Baba A, Nemoto K, Tachikawa H, Hori T, Asada T, Iidaka T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug 30; 30(6):1009-14. PubMed ID: 16644082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.